ARTV revenueFY2025$0
- FY YoY
- -100.0%
ARTV revenue was $0 for fiscal 2025 (ended Dec 31, 2025), down 100.0% from fiscal 2024.
Artiva Biotherapeutics Inc. (ARTV) financials
For fiscal 2025 (ended Dec 31, 2025), Artiva Biotherapeutics Inc. reported $0 of revenue and -$83.86M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$83.86M
- Free cash flow, FY2025
- -$79.34M
- EPS, diluted, FY2025
- -$3.43
- Cash
- $301.45M
- Market cap
- $202.9M
FY2023FY2025
FY2023FY2025
FY2023FY2025
ARTV revenue and earnings growth
ARTV net incomeQ2 2026-$25.00M
ARTV net income was -$25.00M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.25M a year earlier. For the full fiscal 2025 it was -$83.86M, compared with -$65.37M in fiscal 2024.
ARTV EPSQ2 2026-$0.63
ARTV diluted EPS was -$0.63 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$3.43.
ARTV free cash flowQ2 2026-$20.77M
ARTV free cash flow was -$20.77M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$24.04M a year earlier. For the full fiscal 2025 it was -$79.34M, compared with -$55.67M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $251.0K | $33.49M |
| Research and development | $69.54M | $50.33M | $50.25M |
| Selling, general and admin | $20.27M | $17.20M | $13.91M |
| Operating income | -$89.81M | -$67.28M | -$30.67M |
| Pre-tax income | - | -$65.37M | -$28.65M |
| Income tax | $0 | $0 | $72.0K |
| Net income | -$83.86M | -$65.37M | -$28.72M |
| EPS, basic | -$3.43 | -$5.81 | -$35.78 |
| EPS, diluted | -$3.43 | -$5.81 | -$35.78 |
| Diluted shares | 24.4M | 11.3M | 802,747 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $26.70M | $40.49M | $53.76M |
| Short-term investments | $81.31M | $145.19M | $23.47M |
| Receivables | - | $0 | $1.03M |
| Current assets | $112.67M | $188.63M | $79.82M |
| Total assets | $130.94M | $209.58M | $105.11M |
| Current liabilities | $13.09M | $12.25M | $12.23M |
| Total liabilities | $20.97M | $22.94M | $50.72M |
| Shareholders' equity | $109.97M | $186.64M | -$162.01M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$76.75M | -$55.03M | -$47.43M |
| Capital expenditures | $2.59M | $642.0K | $3.26M |
| Free cash flow | -$79.34M | -$55.67M | -$50.69M |
| Investing cash flow | $63.41M | -$120.46M | -$25.98M |
| Financing cash flow | $9.0K | $162.23M | $24.39M |
| Stock-based compensation | $6.82M | $6.98M | $7.05M |
| Depreciation and amortization | $2.60M | $2.43M | $2.27M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | $251.0K | $2.35M | $26.66M |
| Research and development | $21.93M | $19.31M | $16.99M | $17.63M | $17.86M | $17.05M | $13.32M | $13.52M | $12.33M | $11.16M | $11.15M | $13.06M |
| Selling, general and admin | $4.96M | $5.12M | $4.94M | $5.26M | $4.95M | $5.12M | $4.95M | $4.81M | $3.86M | $3.59M | $3.17M | $2.78M |
| Operating income | -$26.89M | -$24.43M | -$21.93M | -$22.90M | -$22.81M | -$22.17M | -$18.27M | -$18.34M | -$16.19M | -$14.49M | -$11.97M | $10.81M |
| Net income | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | -$20.31M | -$16.09M | -$17.47M | -$17.84M | -$13.96M | -$12.00M | $11.28M |
| EPS, basic | -$0.63 | -$0.95 | -$0.85 | -$0.88 | -$0.87 | -$0.83 | - | -$0.92 | -$22.00 | -$17.24 | - | $13.98 |
| EPS, diluted | -$0.63 | -$0.95 | -$0.85 | -$0.88 | -$0.87 | -$0.83 | - | -$0.92 | -$22.00 | -$17.24 | - | $1.62 |
| Diluted shares | 39.4M | 24.7M | - | 24.5M | 24.4M | 24.3M | - | 18.9M | 811,210 | 809,758 | - | 7.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $301.45M | $20.95M | $26.70M | $25.51M | $28.47M | $30.40M | $40.49M | $55.88M | $34.25M | $48.20M | $53.76M | $65.89M |
| Short-term investments | $47.94M | $65.83M | $81.31M | $97.46M | $113.90M | $135.56M | $145.19M | $90.75M | $12.31M | - | $23.47M | - |
| Receivables | - | - | - | - | - | - | $0 | $569.0K | $569.0K | - | $1.03M | - |
| Current assets | $352.28M | $88.74M | $112.67M | $129.52M | $149.07M | $170.00M | $188.63M | $150.56M | $49.75M | - | $79.82M | - |
| Total assets | $368.63M | $105.95M | $130.94M | $148.86M | $169.39M | $191.26M | $209.58M | $225.60M | $75.91M | - | $105.11M | - |
| Current liabilities | $14.58M | $10.88M | $13.09M | $11.12M | $10.77M | $12.20M | $12.25M | $13.29M | $10.83M | - | $12.23M | - |
| Total liabilities | $21.13M | $18.11M | $20.97M | $19.64M | $20.35M | $22.48M | $22.94M | $24.60M | $50.60M | - | $50.72M | - |
| Shareholders' equity | $347.50M | $87.85M | $109.97M | $129.22M | $149.04M | $168.78M | $186.64M | $201.00M | -$191.10M | -$174.67M | -$162.01M | -$151.45M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.36M | -$20.95M | -$14.73M | -$19.20M | -$22.98M | -$19.84M | -$14.65M | -$11.61M | -$13.69M | -$15.09M | -$10.68M | -$10.75M |
| Capital expenditures | $415.0K | $242.0K | $421.0K | $600.0K | $1.05M | $511.0K | $64.0K | $96.0K | $464.0K | $18.0K | $636.0K | $179.0K |
| Free cash flow | -$20.77M | -$21.19M | -$15.15M | -$19.80M | -$24.04M | -$20.35M | -$14.71M | -$11.71M | -$14.15M | -$15.10M | -$11.31M | -$10.93M |
| Investing cash flow | $17.59M | $15.32M | $16.04M | $16.28M | $21.12M | $9.97M | -$966.0K | -$130.63M | $1.35M | $9.78M | -$2.67M | -$493.0K |
| Financing cash flow | $283.27M | -$112.0K | -$121.0K | -$37.0K | -$72.0K | $239.0K | -$30.0K | $163.87M | - | - | $962.0K | $23.43M |
| Stock-based compensation | $1.86M | $1.59M | $1.59M | $1.63M | $1.55M | $2.05M | $2.18M | $1.91M | $1.48M | $1.41M | $1.39M | $1.37M |
| Depreciation and amortization | $692.0K | $666.0K | $666.0K | $662.0K | $641.0K | $628.0K | $614.0K | $627.0K | $603.0K | $587.0K | $594.0K | $556.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% | -74.6% | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | -5773.7% | -509.4% | 40.6% |
| Net margin | - | - | - | - | - | - | - | - | - | -5562.9% | -510.6% | 42.3% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -6017.5% | -481.3% | -41.0% |
| Current ratio | 24.16 | 8.16 | 8.61 | 11.65 | 13.84 | 13.93 | 15.39 | 11.33 | 4.59 | - | 6.53 | - |
Source: XBRL data Artiva Biotherapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ARTV peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ARTV | $0 | -100.0% | -$83.86M | - | $202.9M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.23B | -27.6% | -$3.15B | -141.4% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
ARTV FAQ
8 questionsWhat is ARTV revenue?
Artiva Biotherapeutics Inc. (ARTV) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is ARTV profitable?
No. Artiva Biotherapeutics Inc. reported a net loss of $83.86M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ARTV have?
Artiva Biotherapeutics Inc. reported $301.45M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is ARTV revenue growing?
Artiva Biotherapeutics Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is ARTV free cash flow?
Artiva Biotherapeutics Inc. generated -$79.34M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$76.75M less capital expenditures.What is ARTV earnings per share?
Diluted earnings per share were -$3.43 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ARTV last report financial results?
The latest statements here come from Artiva Biotherapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this ARTV financial data come from?
Quantisnow builds these statements from the structured XBRL data Artiva Biotherapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.